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Abstract
Background: A clonal cell line that combines both stable hepatic function and proliferation
capacity is desirable for in vitro applications that depend on hepatic function, such as
pharmacological or toxicological assays and bioartificial liver systems. Here we describe the
generation and characterization of a clonal human cell line for in vitro hepatocyte applications.
Results: Cell clones derived from human fetal liver cells were immortalized by over-expression of
telomerase reverse transcriptase. The resulting cell line, cBAL111, displayed hepatic functionality
similar to the parental cells prior to immortalization, and did not grow in soft agar. Cell line
cBAL111 expressed markers of immature hepatocytes, like glutathione S transferase and
cytokeratin 19, as well as progenitor cell marker CD146 and was negative for lidocaine elimination.
On the other hand, the cBAL111 cells produced urea, albumin and cytokeratin 18 and eliminated
galactose. In contrast to hepatic cell lines NKNT-3 and HepG2, all hepatic functions were
expressed in cBAL111, although there was considerable variation in their levels compared with
primary mature hepatocytes. When transplanted in the spleen of immunodeficient mice, cBAL111
engrafted into the liver and partly differentiated into hepatocytes showing expression of human
albumin and carbamoylphosphate synthetase without signs of cell fusion.
Conclusion: This novel liver cell line has the potential to differentiate into mature hepatocytes to
be used for in vitro hepatocyte applications.
Published: 21 October 2009
BMC Biotechnology 2009, 9:89 doi:10.1186/1472-6750-9-89
Received: 23 September 2008
Accepted: 21 October 2009
This article is available from: http://www.biomedcentral.com/1472-6750/9/89
© 2009 Deurholt et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
Page 2 of 15
(page number not for citation purposes)
Background
Most pharmacological or toxicological assays and bioarti-
ficial liver support systems require fully differentiated
hepatocytes. The availability of mature human hepato-
cytes is variable and the numbers low, because they are
usually isolated from donor livers not suitable for trans-
plantation. In addition these cells hardly proliferate in
vitro [1,2]. Since mature human hepatocytes cannot be
used for large-scale applications, there is a pressing need
for a cell line that combines highly differentiated hepatic
functions while maintaining adequate proliferation
capacity.
Several cell lines derived from human liver tumours, such
as the hepatoma cell line HepG2 [3], as well as in vitro
immortalized cell lines, like the NKNT-3 cell line, have
been investigated [4,5]. In general, these cell lines prolif-
erate adequately, but the levels of hepatocyte-specific
functions (e.g. urea production from ammonia and cyto-
chrome p450 detoxification activity) remain disappoint-
edly low.
In tumour-derived cell lines, the mutations leading to
immortalization are largely unknown. In an attempt to
control the immortalization process and therefore prevent
at least part of the dedifferentiation process, several
immortalized cell lines have been developed. However,
although certain genetic modifications in immortalized
cell lines are known, spontaneous mutations contributing
to the immortalization cannot be excluded.
For successful in vitro immortalization, overexpression of
cell cycle stimulating genes is generally required. Due to
the low proliferation capacity of mature hepatocytes,
strong stimulation of cell cycle progression is necessary for
immortalization. In the majority of in vitro immortaliza-
tions of primary human liver cells, the gene encoding Sim-
ian Virus 40 Large T antigen (SV40T), an inhibitor of the
cell cycle inhibitors p53 and the Retinoblastoma protein,
has been used [4,6-8]. In addition, overexpression of Cyc-
lin D1, which stimulates cell cycle progression, and dom-
inant negative mutants of p53 have also led to successful
immortalization [9]. In some immortalized cell lines, pro-
liferation was combined with stabilisation of the telom-
eres [10]. Critically short telomeres induce a terminal state
of growth arrest called crisis [11]. Overexpression of the
reverse transcriptase of telomerase, hTERT, stabilizes tel-
omere length, thereby avoiding cellular crisis. As a general
principle immortalization by overexpression of hTERT
only, minimises the reduction in functionality [12].
In contrast to mature human hepatocytes, fetal human
hepatocytes have the ability to proliferate in vitro [13,12]
and thereby can be immortalized without cell cycle stim-
ulation. In addition, telomere stabilisation in itself can
immortalize these cells [12]. Wege et al showed that the
immortalization of fetal human hepatocytes did not affect
their differentiation potential, however, the functionality
of the immortalized cells was not compared with mature
human hepatocytes. Such comparison is essential to
establish the suitability of these cells for hepatocyte appli-
cations  in vitro. Furthermore phenotypical stability of
these cells may be low, since these were not of clonal ori-
gin. In our previous report we demonstrated that primary
human fetal liver cells (HFLCs) in culture exhibit albumin
production rates and hepatocyte specific mRNA levels
comparable to those of primary mature human hepato-
cytes in vitro [14]. However, after eight population dou-
blings most of these functions were decreased to less than
1% of the corresponding function of primary human
hepatocytes in vitro. This functional loss can be, at least
partly, attributed to the presence of non-parenchymal
cells in the cell preparation, which eventually outnumber
the functional hepatocytes. Therefore, selection of func-
tional cell clones is necessary if HFLCs are extensively
expanded in vitro.
In a previous study we already isolated HFLCs and
selected specific clones based on their morphology and
growth potential [14]. This study combines the telomer-
ase based immortalization technique with the selection of
functional HFLCs to obtain new hepatic cell lines. The
resulting immortalized cell line was tested for hepatic
functionality in vitro and in vivo. The in vitro functionality
was compared with other well-known hepatic cell lines,
more specifically the conditionally immortalized NKNT-3
[4] and the tumour derived HepG2 cells [3]. To test
whether the resulted novel immortalized cell line had the
ability to differentiate into functional hepatocytes, the cell
line was transplanted into the spleen of immunodeficient
mice.
Methods
Cell isolation and culture
Human fetal livers were obtained from elective abortions.
Gestational age was determined by ultrasonic measure-
ment of the diameter of the skull and ranged from 14 to
18 weeks. The use of this tissue was approved by the Med-
ical Ethical Committee of the Academic Medical Center,
Amsterdam, the Netherlands, subject to informed patient
consent in compliance with the Helsinki Declaration. We
isolated HFLCs on three independent occasions; in each
case four fetal livers were pooled. Cells were isolated as
described previously [14]. HFLCs were seeded in DMEM
culture medium (Dulbecco's modified Eagle's medium,
BioWhittaker) containing 10% heat-inactivated fetal
bovine serum (HI-FBS, BioWhittaker), 2 mM L-glutamine
(BioWhittaker), 1 M dexamethason (Sigma), 10 g/mL
insulin, 5.5 g/mL transferrin, 6.7 ng/mL selenium-X (ITS
mix, Life Technology), 100 U/mL penicillin, 100 g/mLBMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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streptomycin (penicillin/streptomycin mix, BioWhit-
taker) at a density of approximately 3*105 cells/cm2 in Pri-
maria 6-well plates (BD Falcon). Clonal derivatives were
obtained by limiting dilution. The selection procedure
used and the functionality of the clonal derivatives are
described elsewhere [14]. Near-confluent cultures were
detached by 5 min incubation with 0.25% trypsin/0.03%
EDTA (BioWhittaker) and split at 1:4 ratios. The number
of population doublings (PD) was calculated as PD = log
(Nf/Ni)/log 2, in which Nf is the final number of cells har-
vested and Ni is the number of cells initially seeded. No
corrections were made for cells that did not re-attach after
passaging, since their proportion was negligible. The
period in which PD number progressed linear with cul-
ture time was used to calculate the PD time (TPD).
Mature primary human hepatocytes were isolated from
seven patients undergoing partial hepatectomy, because
of metastatic carcinoma. The tumour free liver tissue used
in each case for the hepatocyte isolation ranged between
2 to 10 grams. The procedure was approved by the Medi-
cal Ethical Committee of the Academic Medical Center
subject to informed patient consent. The hepatocyte isola-
tion method was adapted from the protocol described by
Seglen [15] as previously described [14].
NKNT-3 cells were kindly donated by Prof. I. Fox, Univer-
sity of Nebraska, USA. The NKNT-3 cells were cultured on
Primaria 6-well culture plates (BD Falcon) and in 75 cm2
culture flasks using CS-C complete serum free medium
(Cell Systems Corporation) with 0.2 mg/ml hygromycin B
(Invitrogen) and 1 U/ml penicillin/streptomycin (BioW-
hittaker). Cultures were passaged with a split ratio of 1:5
according to instructions for CS-C medium. Cre-mediated
recombination to revert immortalization of NKNT-3 cells
[4] was carried out by transduction of the adenoviral vec-
tor AxCANCre (Riken DNA Bank (Tsukuba Life Science
Center, Japan) as described previously [5]. We analysed
both reverted, hence transduced with AxCANCre and
selected with G418, and unreverted i.e. untreated cells.
HepG2 cells were obtained from ATCC (HB-8065) and
cultured in Primaria tissue culture flasks in DMEM culture
medium as described above for HFLCs.
All cultures were maintained at 37°C in a humidified
atmosphere (95% air, 5% CO2) and the medium was
changed every 2-3 days.
Introduction of hTERT and Green Fluorescent Protein 
genes
The cDNA of the human telomerase reverse transcriptase
(hTERT) gene, kindly provided by R.L. Beijersbergen,
Netherlands Cancer Institute, the Netherlands, was intro-
duced in the cells by lentiviral transduction. The lentiviral
vector backbone was described as LTRCMVR2 by Marcusic
et al. [16]. The lentiviral vector contained a cytomegalovi-
rus promoter controlling the expression of a reverse tetra-
cycline (Tet) responsive transcriptional activator and a Tet
responsive element controlling the expression of the
hTERT gene. In this system hTERT transcription can be
increased by adding 1 g/mL doxycyclin to the medium.
The lentivirus was produced as previously described [17].
In brief, HEK293T cells were transiently transfected by cal-
cium phosphate precipitation with a third generation len-
tiviral vector system. Virus containing supernatant was
collected at 24 and 48 hours following transfection, fil-
tered through 0.45 m Millipore filters, then 100-fold
concentrated by centrifugation and added to the culture
medium of the HFLCs in 24-well culture plates in a 1:50
(lentivirus preparation:culture medium) ratio. The hTERT
lentivirus was introduced in three independent HFLC cul-
tures and in five clonal derivatives, i.e. cBAL08, cBAL09,
cBAL20, cBAL21 and cBAL29. Cells were passaged twice
before integration of the lentiviral vector was confirmed
by PCR using genomic DNA of transduced cells as tem-
plate.
In the transplantation experiment cBAL111 cells were
marked with Green Fluorescent Protein (GFP) by trans-
duction using lentiviral construct pRRLcpptPGKGFP-
preSsin [17] carrying the GFP gene under control of a
phosphoglycerate kinase promoter. By fluorescence-acti-
vated cell sorting it was demonstrated that  95% of the
transduced cells were GFP positive. There were at least five
passages between transduction with GFP and transplanta-
tion of the cells. The GFP positivity, ratio as well as expres-
sion level, of the cells remained unchanged during
passaging.
Flow cytometry
The cBAL111 cells, cultured for 15 days, were analyzed for
progenitor cell markers by flow cytometry. For compari-
son HepG2 cells were included in the experiment. The
cells were detached using accutase (Innovative Cell Tech-
nologies, Inc., USA), washed twice in DMEM culture
medium, resuspended in 100 l DMEM and incubated for
30 minutes on ice in the dark with 10 l of the following
antibodies: 1. a combination of mouse-anti human
CD34-FITC and mouse-anti human CD326 (EpCAM)-
APC (both Miltenyi Biotech Inc.); 2. a combination of
mouse-anti human CD146-FITC (Miltenyi Biotech Inc.,
USA) and mouse-anti human CD326 (EpCAM)-APC; 3.
mouse-anti human CD133 (Miltenyi Biotech Inc., USA).
The cells incubated with the CD133 antibodies were
washed in culture medium and subsequently incubated
with the secondary antibody goat-anti mouse IgG-Alexa
fluor 488 (Molecular Probes Invitrogen, USA). As negative
controls, cells were incubated with either a combination
of mouse IgG2a-APC and mouse IgG1-FITC (isotype con-BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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trols) (both eBioscience, USA) or with goat-anti mouse
IgG-Alexa fluor 488. The cells were analyzed by flow
cytometry using BD FACScalibur (BD Biosciences, USA)
and data were analyzed with WinMDI 2.8 software.
Hepatocyte function tests
Hepatocyte function tests were performed at confluence
in 6-well plates. After washing the cells twice with phos-
phate buffered saline (PBS, NBPI International) culture
medium was replaced by 2.5 mL of test medium (Wil-
liam's E medium with 4% HI-FBS, 2 mM L-glutamine, 1
M dexamethason, 20 mU/mL insulin (Novo Nordisk), 2
mM ornithine (Sigma-Aldrich), 100 U/mL penicillin, 100
g/mL streptomycin, 0.5 mM NH4Cl, 2.75 mM D-galac-
tose (Sigma), 90 M lidocaine HCl (Sigma-Aldrich).
Medium samples were taken after 0 and 72 hours of incu-
bation. The cells were then washed twice with PBS and
stored at -20°C for protein determination.
Biochemical assays
Urea concentrations were determined using the blood
urea nitrogen test (Sigma Chemical Co). Albumin concen-
trations were determined via enzyme linked immuno-
sorbent assays using cross-absorbed goat-anti-human
albumin antibodies (Bethyl). Lidocaine concentrations
were measured by fluorescence polarization immu-
noassay using a TDxFLx analyzer (Abbot Laboratories).
Galactose concentrations were determined by the absorb-
ance of nicotinamide-adenine dinucleotide (NADH) at
340 nm after enzymatic reaction with galactose dehydro-
genase (Roche). Total protein/well was quantified by
spectrometry using Coomassie blue (Bio-Rad). Produc-
tion rates were established by calculating the changes in
concentration during time and corrected for protein con-
tent.
RT-PCR
RNA was isolated from the cell lines by using TRIzol (Boe-
hringer Mannheim). As a reference, human liver samples
were included in the analyses. First strand cDNA was gen-
erated from 500 ng of total RNA using 20 pmol of gene-
specific RT primers specific for the mRNA of Albumin, -
1-Antitrypsin (AAT), Transferrin, Hepatocyte Nuclear Fac-
tor 4  (HNF4), Alpha-fetoprotein (AFP),  class Glu-
tathione S transferase (GST ) and hTERT in combination
with 5 pmol of RT primer for 18S ribosomal RNA and 134
units Superscript III (Invitrogen). Real-time reverse tran-
scription PCR (RT-PCR) using SYBR green I (Roche) was
performed as described previously [18]. The sequences of
the RT and PCR primers and PCR conditions are given in
Table 1.
Starting levels of mRNA, except for hTERT, were calculated
by analyzing linear regression on the Log (fluorescence)
per cycle number data using LinRegPCR software [19].
Starting levels of hTERT mRNA were calculated by stand-
ard curve analysis, using serial dilutions of hTERT con-
taining plasmid ranging from 102 to 109 copies/reaction
and LightCycler software (Roche). The mRNA starting lev-
els of Albumin, AAT, Transferrin, AFP, GST , and hTERT
were normalised for the starting levels of 18S ribosomal
RNA. Normalised mRNA levels, except for hTERT mRNA
levels, are expressed as a percentage of the mean mRNA
starting levels of the two liver samples normalised for 18S
ribosomal RNA starting levels.
Immunocytochemistry
For the detection of glutamine synthetase (GS), cBAL111
cells were cultured on 8-wells culture-slides (BD Falcon)
for two days. Then the cells were washed twice with PBS
and fixed by a 10-minutes incubation with ice-cold meth-
anol-aceton-water mixture (2:2:1). Cells were incubated
with 70% ethanol for 5 minutes, washed with PBS and
subsequently incubated overnight with monoclonal GS
antibody (Transduction Laboratories, Lexington, KY,
G45020) diluted 1:1000. Antibody binding was visual-
ized with the indirect unlabelled antibody peroxidase
anti-peroxidase (PAP) method [20].
For the detection of albumin, cytokeratin (CK) 18 and
CK19, cBAL111 cells were seeded on Immunoslides (ICN,
Aurora, Ohio, USA) and cultured for two and 15 days.
Cells were washed once in PBS with 0.1% Tween-20 and
fixated in 4% paraformaldehyde in PBS for 15 minutes at
room temperature. Cells were washed as before and incu-
bated with a blocking buffer (3% BSA, 0,2% Fish gelatin
(Sigma), 2%FCS) for one hour at room temperature. After
a further washing step, the cells were incubated with the
primary antibody for one hour at room temperature. As
primary antibodies we used anti-albumin antibody
(Sigma), mouse-anti-human CK18 (sc-6259, Santa Cruz)
and mouse-anti-human CK19 (Santa Cruz) for detection
of albumin, CK18 and CK19, respectively. Cells were
washed again as before and incubated with 28 g/mL Cy2
conjugated goat-anti-mouse IgG and 1 g/mL tetrameth-
ylrhodamine isothiocyanate (TRITC) conjugated phalloi-
din for 1 hour in a humidified chamber at room
temperature. Forty minutes before the end of this incuba-
tion period, 20 ng/mL Diamidinophenylindoldiacetate
(DAPI) was added. Cells were washed again as before and
embedded in Polymount (Polyscience, Washington, USA)
and covered with a coverslip. Slides were analysed using
an Axiovert 200 fluorescence microscope.
Soft Agar assay
Cells were added to 0.35% low-melting-temperature aga-
rose (Seaplaque) containing DMEM culture medium as
described above and transferred at a density of 5000 cells/
well to 6-well plates previously lined with 0.5% agarBMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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Table 1: Primers and conditions used in RT-PCR analysis
Gene Sense primer 5'  
3'
Antisense primer 
5'  3'
Application Size amplicon (bp) PCR conditions
Dilution template Annealing temp. 
(°C)
18S rRNA NA CGAACCTCCGAC
TTTCGTTT
RT NA
AAT NA GGGGGATAGACA
TGGGTATGG
RT NA
AFP NA CGTTTTGTCTTCT
CTTCCCC
RT NA
Albumin NA ACTTCCAGAGCT
GAAAAGCATGGT
C
RT NA
GST NA AGCAGGTCCAGC
AGGTTG
RT NA
HNF4 NA CACTCCAACCCC
GCCCCTC
RT NA
hTERT NA CAGAGCAGCGTG
GAGAGGATG
RT NA
Transferrin NA CCAGACCACACT
TGCCCGCTATG
RT NA
18S rRNA TTCGGAACTGAG
GCCATGAT
CGAACCTCCGAC
TTTCGTTT
PCR 151 1000× 68  63
AAT ACAGAAGGTCTG
CCAGCTTC
GATGGTCAGCAC
AGCCTTAT
PCR 181 - 68  63
AFP TKCCAACAGGAG
GCYATGC
CCCAAAGCAKCA
CGAGTTTT
PCR 306 - 62  55
Albumin TGAGCAGCTTGG
AGAGTACA
GTTCAGGACCAC
GGATAGAT
PCR 189 - 68  63
GST GCCAGAGCTGGA
AGGAGG
TTCTGGGACAGC
AGGGTC
PCR 333 10× 70  63
HNF4 CCGGGTGTCCAT
ACGCATCCT
CAGGTTGTCAATC
TTGGCC
PCR 321 - 68  63
hTERT CGTACTGCGTGC
GTCGGTAT
GGTGGCACATGA
AGCGTAGG
PCR 233 - 68  63
Transferrin GAAGGACCTGCT
GTTTAAGG
CTCCATCCAAGCT
CATGGC
PCR 310 - 68  63
Sequences of the primers used in Reverse Transcriptase (RT) reaction or during real-time PCR reaction (PCR) and the conditions used in the real-
time PCR reactions. NA = not applicable.BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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DMEM culture medium. After 15 days, the colonies were
stained with 0.005% Crystal violet and counted.
Transplantation
The cBAL111 cells overexpressing GFP were transplanted
into four 6 week old Rag2-/-c-/- mice [21]. The mice were
anesthetized with an intraperitoneal injection of FFM
mixture (2.5 mg Fluanisone/0.105 mg Fentanyl citrate/
0.625 mg Midazolam HCl/kg in H2O, 7 mL/kg). One mil-
lion GFP-marked cBAL111 cells suspended in 100 L
HBSS were injected into the inferior tip of the spleen as
described [22]. At both nine and 34 days after transplan-
tation, two mice were sacrificed. The livers and spleens
were harvested after in vivo fixation. For in vivo fixation,
mice were anesthetized as described above and 25 mL PBS
was flushed trough the circulation, followed by 25 mL 2%
paraformaldehyde (PFA) in PBS. Subsequently, liver and
spleen were harvested and cut into pieces of approxi-
mately 0.2 cm3. The tissue pieces were incubated in 4%
PFA in PBS for four hours, followed by an overnight incu-
bation in 30% sucrose solution. Tissues were snap frozen
in liquid nitrogen and stored at -80°C.
Immunohistochemistry
Cryosections were 6 m thick and were mounted on poly-
L-lysine coated slides. Sections were incubated in Teng-T
(10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin
and 0.05% Tween-20, pH 8.0) for 30 minutes before incu-
bation with primary antibodies. Human mitochondria
were visualized with a mouse-anti-human mitochondria
antibody (Chemicon International) in a 150-fold dilu-
tion; vimentin was visualized with a mouse-anti-vimentin
antibody, clone 9 (Boehringer Mannheim) in a 1000-fold
dilution; carbamoylphosphate synthetase (CPS) was visu-
alized with rabbit-anti-CPS antibody in a 1500-fold dilu-
tion and glutamine synthetase (GS) was visualized with
monoclonal GS antibody (Transduction Laboratories) in
a 500-fold dilution, human albumin was visualized with
goat-anti-human albumin antibody in a 1:200 fold dilu-
tion. As a secondary antibody Alexa594 conjugated goat-
anti-mouse IgG (Molecular Probes) was used in a 1000-
fold dilution for the detection of vimentin and human
mitochondria and in a 250-fold dilution for detection of
GS. CPS antibodies were detected with Alexa594 conju-
gated goat-anti-rabbit IgG (Molecular Probes) in a 250-
fold dilution. Goat-anti-human albumin immunoglobu-
lins were detected using rabbit-anti-goat IgG conjugated
with Alexa 594 (Molecular Probes). Slides were mounted
in Vectashield containing 1 g/mL 4,6-diaminidino-2-
phenylindole (DAPI) to counterstain DNA.
FISH analysis
Fluorescent in situ hybridization (FISH) analysis was per-
formed on 6 m sections of paraffin embedded liver tissue
as described before [23]. Briefly, sections were treated to
remove paraffin and the sections were denatured in 70%
formamide for 2.5 minutes. 150 ng Biotin 11-dUTP
labeled human genomic DNA, 200 ng digoxigenin 11-
dUTP labeled murine genomic DNA and 5 g salmon
sperm DNA were denatured together and hybridized over-
night at 37°C with the sections. After washing the slides,
human DNA was visualized with FITC anti-avidin fol-
lowed by biotinylated anti-avidin antibodies (Vector lab-
oratories), whilst mouse genomic DNA was visualized
with sheep rhodamine anti-digoxigenin followed by Texas
red anti-sheep antibodies (Vector laboratories). Slides
were mounted in Vectashield (Vector laboratories) con-
taining 1 g/mL DAPI to counterstain DNA.
Statistical analysis
Student's t tests were used to determine statistical differ-
ences. Significance was reached if P < 0.05. SPSS 12.0.1
(SPSS Inc., Chicago, IL, USA) was used for statistical anal-
ysis. Average values (± standard error) are reported.
Results
Human TERT introduction in HFLCs and clonal derivatives
The maximum number of PDs between the HFLC prepa-
rations and clonal derivatives were different. Expression
of hTERT was detected in some of the clonal derivatives
analysed, however, all HFLCs and clonal derivatives even-
tually entered a state of terminal growth arrest (Table 2).
After lentiviral introduction of the hTERT gene, the pres-
ence of the hTERT cDNA was confirmed in HFLCs and
clonal derivatives by PCR on genomic DNA (results not
shown). However, the HFLC cultures did not overcome
the terminal growth arrest after the introduction of the
hTERT gene; only one of the HFLC cultures' lifespan was
extended by 30%. In addition, only one of the clonal
derivatives was able to overcome the terminal growth
arrest after the introduction of hTERT. This clone, cBAL08,
previously showed the longest life span of 61 PDs and a
relatively high endogenous hTERT expression (Table 2).
Because the transduced cell line was capable of more than
120 PDs, which is twice the life span of the parental cell
line cBAL08, and still did not show any sign of growth
arrest, we considered this cell line to be immortalized and
named it cBAL111. The hTERT mRNA levels of cBAL111
were 1 × 105-fold higher as compared to its parental cell
line cBAL08 (Table 2).
Characterisation of cBAL111 in vitro
The organisation of the cBAL111 cell layer changed during
culturing; the cells displayed a cubic shape at day 15 (Fig.
1C and 1D) instead of the more spindle shape at day 2
(Fig. 1A and 1B). The cBAL111 cultures were 100% posi-
tive for the hepatocyte markers GS, CK 18 and albumin as
well as the cholangiocyte marker CK 19 at day 2 and day
15 after seeding (GS and albumin are shown at day 2 andBMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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CK18 and CK19 are shown at day 15 in Fig. 1). The CK18
staining was predominantly around the nucleus reaching
into the cytoplasm, which is similar to the CK18 staining
of primary human hepatocytes that are dedifferentiating
in vitro [24]. These data suggest that under these condi-
tions the cBAL111 cells resemble cells with progenitor
characteristics rather than fully differentiated hepatocytes.
The 15 day-cultured cBAL111 cells and, for comparison,
hepatoblastoma derived HepG2 cells were characterized
for three progenitor cell markers by flow cytometry, i.e.
CD146, a marker for various cells including mesenchymal
progenitor cells and hepatocytes during liver regeneration
[25,26], CD326 (EpCAM), an epithelial marker upregu-
lated in gastrointestinal carcinomas [27] and CD133, a
marker for progenitor cells of various origins, like
endothelial cells, haematopoietic cells and neural cells
[28]. The cBAL111 cells were positive for CD146, but neg-
ative for CD326 (EpCAM) (Fig. 2A and 2B) and CD133
(data not shown). HepG2 cells were also negative for
CD133 (data not shown), but, in contrast to the cBAL111
cells, positive for CD326 and negative for CD146 (Fig. 2C
and 2D).
Because the immunostainings suggested a transition in
the organisation of the cell layer of cBAL111 cells, we
tested their in vitro functionality at 2 days of culture,
when the cells displayed a spindle like morphology and
the culture was not confluent and at day 15, when cells
were more cubic and confluence was reached. There was a
trend of increased expression of markers for mature hepa-
tocytes (production of albumin and urea, galactose elimi-
nation and transcript levels of transferrin, AAT and HNF)
with culture time and decreased expression of markers for
immature hepatocytes (GST and AFP) (Table 3). The in
vitro  functionality of cBAL08 after reaching confluence
was comparable with that of cBAL111, particularly at day
15; no significant difference was detected between cBAL08
and cBAL111 at day 15 for urea and albumin production
and the mRNA levels of Albumin, AAT, Transferrin, GST
and AFP differed less than 2.5-fold (Table 3). So, the
immortalization of cBAL08 maintained the investigated
hepatic functions. Further extension of the culture period
did not clearly increase hepatic functionality (results not
shown).
To investigate the putative tumorigenicity of cBAL111, the
cells were seeded in soft agar. The cBAL111 cells were not
able to form colonies in soft agar, where HepG2 as posi-
tive control, formed 61 ± 21 colonies from 5000 cells. The
inability of cBAL111 cells to grow in an anchorage inde-
pendent way, is an indication that cBAL111 cells are not
tumorigenic.
Comparison of cBAL111 with other hepatic cell lines and 
mature hepatocytes
The novel in vitro immortalized fetal hepatocyte cell line
cBAL111 was subsequently compared with HepG2 cells,
the conditionally immortalized hepatocyte cell line
NKNT-3 and primary (mature) human hepatocytes two
days after seeding. The primary human hepatocytes did
not exhibit any decline in the tested functions within two
days (results not shown). HepG2, cBAL111 at day 15 and
NKNT-3 cells, both un-reverted and reverted for immor-
talization, synthesized urea, at a level 11-32 fold lower
than mature hepatocytes (Table 3). The HepG2 cells and
to a lesser extent the cBAL111 cells produced albumin in
contrast to NKNT-3 cells. The galactose elimination of the
cBAL111 cells at day 15 reached to 19% of the levels of the
mature hepatocytes. The cBAL111 cells, like fetal hepato-
Table 2: The life span and the hTERT mRNA levels of three different HFLC isolates, clonal derivatives and cBAL111
Cell source Maximal PDs hTERT mRNA copies/18S rRNA copies
HFLCs, 16 weeks 57.6 ± 10.2 Undetectable (n = 4)
cBAL08 61 2.7 *104 (n = 1)
cBAL09 30 Not determined
cBAL20 38 Undetectable (n = 1)
cBAL21 31 Undetectable (n = 1)
cBAL29 42 2.4 *105 ± 1.9 *105 (n = 3)
cBAL111 Immortal 2.6 *109 ± 3.2 *108 (n = 4)
Life span is indicated as the maximum number of population doublings (PDs).BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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cytes, did not eliminate lidocaine, a marker for cyto-
chrome P450 1A2 and 3A4 activity, whereas the mature
hepatocytes eliminated 9.8 ± 9.3 nmol/h/mg protein.
In cBAL111 and NKNT-3 cells, the mRNA levels of albu-
min, AAT and transferrin, (markers of hepatocyte differen-
tiation) were less than 1% of the corresponding levels in
human liver. However, the transcript levels of HNF4, a
master regulator of liver development, increased up to
17% of the human liver levels in the cBAL111 cells at day
15. HepG2 cells showed mRNA levels for albumin, AAT
and transferrin that were comparable to human liver. As
markers associated with immature hepatocytes, AFP
mRNA levels of cBAL111 and NKNT-3 cells were compa-
rable to the in vivo level, while the GST  mRNA levels
were 10-44 times higher. In HepG2 cells, mRNA levels for
AFP were 1000-fold higher than the in vivo levels and GST
 levels were undetectable. In summary cBAL111 at day
Immunostainings of cBAL111 cells in vitro Figure 1
Immunostainings of cBAL111 cells in vitro. The cells were stained using antibodies against GS (A) (blue, 40× magnifica-
tion, 2 days in culture), albumin (B, C) (green, 400× magnification, 2 days in culture) and CK19 (D) or CK18 (E, F) (both green, 
400× magnification, 15 days in culture). In the CK18, CK19 and albumin staining, cells were further visualized by phalloidin, 
binding to actin (red), and DAPI, binding to the nuclei (blue) (B, D, E). Corresponding single stains of albumin and CK18 are 
shown in C and F.BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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15 was positive for all tested hepatocyte parameters,
whereas HepG2 and NKNT-3 cells both lacked one func-
tion.
cBAL111 cells differentiate into functional hepatocytes in 
murine liver
To determine whether cBAL111 cells have the potential
for hepatic differentiation, the cells were marked with GFP
by lentiviral transduction and transplanted in the spleen
of 4 immunodeficient mice. Nine and 34 days after trans-
plantation, GFP expressing cells were detected in the
murine spleen (results not shown) and liver (Fig. 3A and
3B). The presence of GFP positive cells in the murine livers
was relatively low (~1%), since no liver repopulation
model was applied, and remained stable between nine
and 34 days. The cells appeared as single cells and no cell
clusters were detected, which again suggested a lack of
tumorigenicity.
The majority of these cells exhibited an elongated mor-
phology, however a small number of cells (~1%) had the
morphological characteristics of hepatocytes, given their
cuboid appearance. No differences were observed
between the livers harvested at nine and 34 days after
transplantation. The GFP positive cells were confirmed to
be from human origin by immunohistochemistry using a
human specific antibody binding to mitochondria (Fig.
3C and 3D). Immunohistochemistry using an antibody
against vimentin, a marker for dedifferentiated and mes-
enchymal cells [29], indicated a high expression in
cBAL111 in vitro (data not shown) and in all the elongated
cBAL111 cells found in the mouse liver, whereas the
cBAL111 cells with cuboid appearance did not or hardly
expressed vimentin (Fig. 3E). Furthermore these GFP pos-
itive hepatocyte-looking cells with cuboid morphology
were indistinguishable from the surrounding mice hepa-
tocytes with regards to CPS expression, which is expressed
periportally [30] (Fig. 3F). In contrast, elongated cBAL111
cells did not express CPS. GS expression, which is present
in vitro (Fig. 1), was absent in the transplanted cells in the
periportal areas (Fig. 3G). No GFP positive cells were
detected in pericentral areas, the site of GS expression in
Dotplots of flow cytometry analysis of CD146 and CD326 expression of cBAL111 cells (A, B) and HepG2 cells (C, D) Figure 2
Dotplots of flow cytometry analysis of CD146 and CD326 expression of cBAL111 cells (A, B) and HepG2 cells 
(C, D). (A, C) Negative isotype controls, (B, D) cells labeled with anti-CD146-FITC and anti-CD326-APC.
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normal liver. A possible explanation for this is that the
cells may have entered the liver via the portal vein and
engrafted before reaching the pericentral area. Finally, the
cuboid GFP positive cells stained positive for human
albumin (Fig. 3H-J), whereas the elongated GFP positive
cells were negative (not shown).
We then tested whether the GFP positive hepatocytes were
the result of fusion between human cBAL111 cells and
murine hepatocytes [31], by using FISH analysis. The
results showed that nuclei reacting to the human probe
(Fig. 4A and 4D) were negative for the murine probe (Fig.
4C and 4F). From the shape of the nuclei and the localiza-
tion of cells, we concluded that these were cBAL111
derived hepatocytes.
Discussion
In this report we present a novel, clonal, immortalized
human fetal liver cell line, cBAL111, that displays hepato-
cyte-specific functions. In vitro, the cBAL111 cell line pro-
duced albumin and urea and expressed hepatocyte-
specific genes. However, the levels of the hepatic func-
tions showed considerable variation compared with pri-
mary mature hepatocytes. Moreover, the cBAL111 cells
expressed immature markers CD146, cytokeratin 19 and
glutathione S transferase , but did not show any evidence
of growth in soft agar. In vivo, when cBAL111 was trans-
planted in immunodeficient mice, the cell line showed
the potential to fully differentiate into hepatocytes and
adapt the zonal expression pattern of CPS.
Human fetal liver cells have been immortalised by telom-
erase activation before [12], but this is the first report in
which this immortalisation strategy was combined with a
cloning procedure. In contrast to Wege et al. we could not
immortalise unselected HFLC preparations [12], although
we were able to extend the life span of the cells by about
30%. In our study we selected cells with cuboid morphol-
ogy from the initial cell preparation and of these selected
cells only the cell line with the highest proliferation capac-
ity, cBAL08, became immortal by overexpression of
hTERT. The reduced ability of immortalization in the
present study may be the result of differences in transduc-
tion levels observed in the two studies. Wege et al used a
constitutively active Moloney murine leukemia promoter
to drive hTERT expression [12]; we used a tetracycline
inducible expression system, stimulated with 1 M doxy-
cyclin, to drive hTERT expression. Because Moloney
Table 3: Hepatic functions of different hepatic cell lines and primary mature human hepatocytes (Mat Hep)
Hepatic function (n = 9) mRNA levels (n = 3)
Mature hepatic marker
mRNA levels (n = 3)
Immature hepatic 
marker
Cell Albumin 
production
(ng/h/mg 
protein)
Urea 
production
(nmol/h/
mg 
protein)
Galactose 
elimination
(mol/h/
mg 
protein)
Albumin Transferrin AAT HNF4 GST AFP
Mat Hep 37.7 ± 7.7 91.5 ± 33.7 0.58 ± 0.44 130 245 121 141 535 ND
cBAL08 0.3 ± 0.4 4.0 ± 1.6 ND 0.02 ± 0.01 0.20 ± 0.14 0.32 ± 0.14 ND 1000 ± 565 78 ± 61
cBAL111
day 2
Undetectabl
e
Undetectabl
e
0.04 ± 0.02 0.02 ± 0.01 0.11 ± 0.05 0.02 ± 0.01 1.3 ± 1.3 1944 ± 1010 122 ± 11
cBAL111
day 15
0.7 ± 0.8 8.0 ± 6.6 0.11 ± 0.03* 0.02 ± 0.01 0.20 ± 0.06 0.05 ± 0.01 17.2 ± 5.6* 1374 ± 671 114 ± 10
HepG2 2.8 ± 0.3 4.7 ± 0.2 ND 63 ± 6 896 ± 110 199 ± 56 ND Undetectabl
e
93353 ± 
13228
NKNT-3 
reverted
Undetectabl
e
4.9 ± 9.4 ND 0.24 ± 0.22 0.16 ± 0.12 0.92 ± 1.52 ND 952 ± 1164 117 ± 166
NKNT-3 
unreverted
Undetectabl
e
2.9 ± 5.2 ND 0.42 ± 0.66 0.20 ± 0.13 0.26 ± 0.34 ND 4427 ± 5366 65 ± 79
MessengerRNA levels are expressed as a percentage of the mean mRNA levels of the two liver samples. ND = not determined
* cBAL111 day 2 versus cBAL111 day 15; P < 0.05BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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Figure 3 (see legend on next page)BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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murine leukaemia vectors are prone to transduce rapidly
dividing cells, this might have resulted in the selection of
cells prone to immortalization.
Our results are in line with the conclusion of Wege et al
that telomerase-induced immortalization of HFLCs does
not affect their differentiation potential [12]. After
immortalisation, cBAL111 was capable of reaching urea
and albumin production rates and the hepatocyte specific
mRNA levels comparable to the levels of cBAL08. How-
ever, cBAL111 needs prolonged cultivation time to pro-
duce albumin and urea. In addition, galactose
elimination increased after prolonged culturing. This may
be related to the increased transcript levels of HNF4, a
key regulator of hepatocyte development and function
[32].
Furthermore, we found no indications that cBAL111 was
malignantly transformed; cBAL111 was not able to form
colonies in soft agar and no tumours were found in
immunodeficient mice 34 days after transplantation. We
conclude that telomerase reconstitution can immortalize
fetal human hepatocytes without loss of function and
without indications of malignant transformation.
To our knowledge this is the first time that a hTERT-
immortalized human fetal liver cell line was evaluated for
hepatic function in vitro. The clonal origin of the cell line
is most important for preservation of the phenotype dur-
ing long-term culturing. The stability in phenotype was
previously shown for cBAL08 [14]. This is in contrast to
cultures of hepatocyte isolates from mature or fetal origin,
either immortalized or not.
In addition to the description of cBAL111, we compared
its functionality with that of mature human hepatocytes
kept under the same culture conditions. It is rather sur-
prising that such comparison is rarely seen in similar stud-
ies describing hepatic cell lines. Mature hepatocytes are
currently the only cells that meet the criteria for in vitro
applications and therefore are the gold standard when
evaluating alternative hepatic cell lines. The performance
of our novel hepatocyte line cBAL111 was also compared
with two well-known and widely used hepatic cell lines,
NKNT-3 [4] and HepG2 [3]. Admittedly all three cell
lines, performed considerably less well compared with
primary mature human hepatocytes in all the liver param-
eters tested in this study. NKNT-3 cell did not produce
detectable levels of albumin; HepG2 cells lacked detecta-
ble GST  expression. In concordance with the low level of
hepatic differentiation, relatively high mRNA levels of
AFP and particularly GST  were observed in cBAL111.
Moreover the cBAL111 cells expressed CK19, a marker for
cholangiocytes, and in addition CK18, a marker for hepa-
tocytes, in a pattern characteristic of de-differentiated
human hepatocytes. Finally, the cBAL111 cells expressed
CD146, a marker of various cells, including mesenchymal
progenitor cells [25], Therefore it can be concluded that
cBAL111 cells are not fully differentiated in vitro into
mature hepatocytes, but rather should be regarded as a
progenitor liver cell line that has the full potential to dif-
ferentiate into hepatocytes. These cells may derive from
mesodermal cells, as also suggested for multipotent pro-
genitor cells previously isolated from human fetal liver
[33].
Interestingly, HepG2 and cBAL111 showed contrasting
expression patterns of CD146 and CD326. Both mem-
brane glycoproteins are expressed on progenitor cells.
However, CD326 is heavily upregulated in premalignant
hepatic tissues and hepatocellular carcinomas and a
marker for tumor-initiating stem cells, in contrast to
CD146 [34,27,35]. Expression of CD146 is low in mature
hepatocytes, but is upregulated in the termination phase
of liver regeneration and in primary hepatocytes in the
presence of transforming growth factor (TGF)-1. These
observations underline the non-transformed phenotype
of cBAL111 cells in contrast to HepG2 cells.
The liver provides an optimal environment for hepatic dif-
ferentiation of cBAL111. When cBAL111 cells were
labelled with GFP and transplanted into the spleen of
Immunofluorescence of mouse livers (40× magnification), harvested 9 days after transplantation of GFP marked cBAL111 cells  (green) Figure 3 (see previous page)
Immunofluorescence of mouse livers (40× magnification), harvested 9 days after transplantation of GFP 
marked cBAL111 cells (green). Nuclei were visualized by DAPI staining (blue) (A-F, I). The majority of cells exhibited an 
elongated morphology (arrows); a small number of cells adapted hepatocyte morphology (arrowheads, A and B). Human origin 
of the cells was confirmed using an antibody against human mitochondria (red) (C and D); Human mitochondria fluorescence 
(C), GFP fluorescence (C insert) and merge of human mitochondria and GFP fluorescence (D, insert shows higher magnifica-
tion). With hepatic differentiation, the cells lost the expression of vimentin, a marker of undifferentiated mesenchymal cells 
(red; insert shows single stain) (E). Hepatocytes originating from cBAL111 are undistinguishable from the surrounding murine 
hepatocytes in CPS expression (red) (F). No cells originating from cBAL111 were found in pericentral regions; cBAL111 in vivo 
did not express GS (G). Transplanted cBAL111 cells with hepatocyte morphology showed co-localization of GFP and human 
albumin (red) (H-J); albumin fluorescence (H), GFP fluorescence (I) and merge of albumin and GFP fluorescence (J). P, portal 
vein; C, central vein.BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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immunodeficient mice the cells migrated to the liver. This
was already shown with human fetal hepatocytes, both
immortalized and freshly isolated [36,12]. However, in
this study we showed that following engraftment a
number of these cells went to become hepatocytes mor-
phologically indistinguishable from murine hepatocytes.
These cells had very low or no expression of vimentin, a
marker for mesenchymal cells and for the undifferentiated
cBAL111 cells. In addition, the cuboid cells expressed
human albumin and adapted the zonal expression pattern
of CPS and GS characteristic for the surrounding cells
[30]. With FISH analysis, we excluded the possibility that
these GFP positive hepatocytes were the result of fusion
between GFP labelled cBAL111 cells and murine hepato-
cytes. Fusion between host liver cells and transplanted
stem cells, specifically haematopoietic stem cells, has
been widely reported to account for high rates of transdif-
ferentiation [37,31]. Our experiments confirm that the
cBAL111 line is able to differentiate into hepatocytes
when the right differentiation stimuli are present.
However, the fact that a significant number of the trans-
planted cells did not adapt the hepatocyte morphology
and expressed high levels of vimentin, but no human
albumin, suggests that either not all cBAL111 cells were
equally sensitive to differentiation stimuli, despite the
FISH analysis (40× magnification) of mouse livers after transplantation of GFP marked cBAL111 cells Figure 4
FISH analysis (40× magnification) of mouse livers after transplantation of GFP marked cBAL111 cells. The 
probe hybridizing with human DNA was visualized using a FITC labeled antibody (A, B, D and E), showing green nuclei, the 
probe hybridizing with murine DNA was visualized using a Texas Red labeled antibody (red nuclear staining on top of cytoplas-
mic background autofluorescence, B, C, E and F). All nuclei were counterstained using DAPI (blue A, C, D and F). Picture sets 
A-C and D-F both show a human cell that is negative for the murine DNA.BMC Biotechnology 2009, 9:89 http://www.biomedcentral.com/1472-6750/9/89
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clonal origin of the cells, or that not all cells were exposed
to the same levels of differentiation stimuli due to micro-
environmental variations. This requires further investiga-
tion.
Very recently we have tested the cBAL111 cells in the
AMC-bioartificial liver (AMC-BAL), which is a bioreactor,
more suitable for hepatocyte culturing than monolayer
culturing [38,39]. We showed that the cBAL111 cells elim-
inated ammonia and galactose at a rate up to 49% and
90% of that of primary porcine hepatocytes in the AMC-
BAL, respectively. Other functions, like albumin produc-
tion and lidocaine elimination only reached 6% and 0.1%
of the levels of primary porcine hepatocytes in the AMC-
BAL. This further underlines that the cBAL111 cells are
indeed hepatocyte-like cells which probably need further
stimulation of hepatic differentiation for in vitro applica-
tions.
Conclusion
The development of a cell line that combines both in vitro
hepatic function and proliferation capacity is important
for large-scale applications that depend on in vitro hepatic
functionality. In this study we present evidence of a novel
cell line cBAL111, which is a telomerase immortalized
fetal human hepatocyte cell line capable to differentiate
into mature hepatocytes in vivo. The potential of this novel
cell line merits further investigation. The challenge is to
define the best possible experimental conditions in vitro to
mimic as closely as possible the differentiation stimuli
present in vivo aiming to achieve a high degree of differen-
tiation into mature hepatocytes in vitro.
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